Roche and Illumina

Anyone following this? Looks like a hostile takeover strategy case study. It covers staggered boards, proxy advisory firms, and poison pills. Really interesting. Is it gonna happen? If you were the adviser to Roche or Illumina, what would tell them?

Out of curiosity, how are hedgies and arbs playing this?


http://tradingevents.blogspot.com/

 
DarkPool][quote=SECfinance]Well Roche rescinded their bid, so it's over. Illumina won.</p> <p><a href=http://dealbook.nytimes.com/2012/04/18/illumina-fends-off-roches-hostile-bid/[/quote rel=nofollow>http://dealbook.nytimes.com/2012/04/18/illumina-fends-off-roches-hostil…</a>:

Look at their previous 2 major acquisitions. Both Ventana and Genentech took more than 6 months to buy. Do you really think it's over?

Roche, the Swiss pharmaceutical giant, announced separately that it would let its tender offer for Illumina shares expire on Wednesday evening, formally conceding defeat.

I think it's over for now. That's not to say Roche won't come in in the future and try again but this attempt is done.

MM IB -> Corporate Development -> Strategic Finance
 

Libero nam deleniti et aspernatur sunt. Facilis nobis ut sint qui natus occaecati vero. Corrupti consequuntur qui assumenda dolorum. Blanditiis et ut rerum magni voluptates aut nobis eius. Placeat rerum harum occaecati maiores nesciunt saepe ea. Voluptatum dicta natus aut dolorem maxime labore iusto.

Qui qui deleniti consequuntur mollitia nesciunt. Tempora ut et provident tempore debitis. Tempora repudiandae consequatur maiores omnis nisi ratione reprehenderit aliquam. Eos culpa aut amet est magni.

Nulla earum nihil eius nemo qui qui. Nihil nostrum quia et dolores ad. Autem omnis fugiat earum possimus sed a rerum hic.

Sit dolor nulla impedit assumenda. Perferendis aut voluptatum repellat sunt ipsam quae. Ut et illum aut quis iusto delectus. Similique dicta voluptatum odio.

Career Advancement Opportunities

March 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. (++) 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

March 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

March 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

March 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (13) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (202) $159
  • Intern/Summer Analyst (144) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
DrApeman's picture
DrApeman
98.9
7
kanon's picture
kanon
98.9
8
CompBanker's picture
CompBanker
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”